Results 221 to 230 of about 3,128,729 (335)

Use and Patient-Reported Outcomes of Clinical Multigene Panel Testing for Cancer Susceptibility in the Multicenter Communication of Genetic Test Results by Telephone Study [PDF]

, 2018
Michael J. Hall, Linda Patrick‐Miller, Brian L. Egleston, Susan M. Domchek, Mary B. Daly, Pamela Ganschow, Generosa Grana, Olufunmilayo I. Olopade, Dominique Fetzer, Amanda Brandt, Rachelle Chambers, Dana Clark, Andrea Forman, Rikki Gaber, Cassandra Gulden, Janice Horte, Jessica M. Long, Terra Lucas, Shreshtha Madaan, Kristin Mattie, Danielle McKenna, Susan Montgomery, Sarah M. Nielsen, Jacquelyn Powers, Kim Rainey, Christina Rybak, Michelle Savage, Christina Seelaus, Jessica Stoll, Jill E. Stopfer, Xinxin Yao, Angela R. Bradbury   +31 more
openalex   +1 more source

Intermediate-term hip survivorship and patient-reported outcomes of periacetabular osteotomy: The Washington University Experience [PDF]

, 2018
Clohisy, John C, Duncan, Stephen, Goss, Charles W, Schoenecker, Perry, Thomason, Kayla, Wells, Joel   +5 more
core   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe. [PDF]

Blood Adv
Pennings ERA, Spanjaart AM, Thielen FW, Oerlemans S, Fleischer A, Sanges C, Gomes Da Silva M, Cabrerizo Y, Lecot P, Roux-Opstaele L, Dreuillet C, Gonzalez-Marcano E, Millán O, Jaeger U, Delgado J, Luu M, Huber B, Lorrain M, Pina M, Kremer A, Bolaños N, Clavreul S, Nier S, Liu RDK, Lissenberg-Witte BI, Anguille S, Robin M, Morris EC, Sureda A, Préau M, Pannard M, De Bock GH, Wagers SS, Negre H, Maucort-Boulch D, Hudecek M, Uyl-de Groot CA, Kersten MJ.   +37 more
europepmc   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Exploring patient-reported outcomes to assess progress in inpatient low vision rehabilitation. [PDF]

J Patient Rep Outcomes
van Munster EPJ, Schilderman ABM, van Nispen RMA, Roelofs AAJ, Bootsma AM, van der Aa HPA.   +5 more
europepmc   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

The impact of early life stress on patient-reported outcomes in multiple sclerosis. [PDF]

Mult Scler J Exp Transl Clin
Goldman M, Chen S, Pearsall R, Neigh G, Oh U.   +4 more
europepmc   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Symptoms, side effects, quality of life and financial toxicity matter to patients with cancer, we need to do a better job of capturing and reporting these concepts in trials and clinical care

BMJ Oncology
Melanie Calvert, Roger Wilson, John Devin Peipert   +2 more
doaj   +1 more source